Comparison of Once Daily 40 mg Torsemide With Twice-daily 40 mg Furosemide
NCT ID: NCT03509545
Last Updated: 2024-04-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
20 participants
INTERVENTIONAL
2021-06-30
2022-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Within Subject Variability Study of ER Torsemide 20 mg Tablet in Healthy Subjects
NCT03214874
Hypertension Study: Multinational Torasemide Trial in Mild to Moderate Hypertension.
NCT00334386
Investigator Initiated Randomized Open-label Comparative Study of Britomar (Prolonged Release Torasemide) and Diuver (Torasemide) to Assess Effects on Natriuresis and Central Hemodynamics.
NCT02087332
Study to Evaluate the Trough and Peak Effect of Once Daily Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) by Ambulatory Blood Pressure Monitoring (ABPM) in Patients With Mild to Moderate Essential Hypertension
NCT00257491
Bioequivalence Study Between GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Tablets and Reference Product in Healthy Adult Participants Under Fasting Conditions
NCT03031496
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CHF Patients: ER Torsemide 40 mg
CHF patients will be given 40 mg ER Torsemide
CHF Patients: ER Torsemide 40 mg
ER Torsemide 40mg given once daily to CHF patients
CHF Patients: Furosemide 40 mg
CHF patients are on 40 mg of Furosemide
CHF Patients: Furosemide 40 mg
Stable CHF patients taking twice-daily 40 mg Furosemide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CHF Patients: ER Torsemide 40 mg
ER Torsemide 40mg given once daily to CHF patients
CHF Patients: Furosemide 40 mg
Stable CHF patients taking twice-daily 40 mg Furosemide
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
70 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sarfez Pharmaceuticals, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anil K, MD
Role: PRINCIPAL_INVESTIGATOR
Syngene
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Syngene International
Bangalore, Karnataka, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CLCD-075-17
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.